SCHEMBL20173760

SCHEMBL20173760

CC(C)c1cccc(C(=O)NS(=O)(=O)N(C)C)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KAT6A Q92794 3/20 0.54
TP53BP1 Q12888 1/20 0.47
NLRP3 Q96P20 1/20 0.46
HTT P42858 1/20 0.44
SCN9A Q15858 3/20 0.44
PTGER3 P43115 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
CASP3 P42574 1/20 0.42
SENP8 Q96LD8 1/20 0.42
SENP7 Q9BQF6 1/20 0.42
SENP6 Q9GZR1 1/20 0.42
CA2 P00918 1/20 0.41
ALDH1A1 P00352 1/20 0.41
GAA P10253 1/20 0.41
LMNA P02545 1/20 0.40
MAPT P10636 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13209252 0.83 KAT6A (0.58) KAT6ATP53BP1HTTSCN9APTGER3
SCHEMBL19333622 0.81 LMNA (0.50) NLRP3SCN9AMEN1KMT2ANPC1
SCHEMBL10763198 0.80 HTT (0.48) HTTSCN9AMEN1KMT2ANPC1
SCHEMBL20118983 0.80 HDAC8 (0.62) KAT6AHTTMEN1KMT2ANPC1
SCHEMBL14367222 0.79 HDAC6 (0.59) KAT6ATP53BP1NPC1RAB9ASMN1; SMN2
SCHEMBL30755385 0.77 HDAC1 (0.52) KAT6AHTTSCN9AMEN1KMT2A
SCHEMBL20173758 0.77 KAT6A (0.52) KAT6ATP53BP1SCN9APTGER3
SCHEMBL20173764 0.77 CA2 (0.59) HTTMEN1KMT2ACA2
SCHEMBL20119312 0.77 SMN1; SMN2 (0.45) HTTSCN9AMEN1KMT2ANPC1
SCHEMBL20178601 0.77 KAT6A (0.54) KAT6AHTTSCN9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10597391-B2 Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof ENANTA PHARMACEUTICALS, INC. (US) 2020-03-24 US disclosed
US-20180141941-A1 UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2018-05-24 US disclosed
US-20180141941-A1 UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2018-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180141941-A1 UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF NR1H4, FXR1, SLC10A1 KAT6A 2864/4885TP53BP1 4448/4885NLRP3 1663/4885
US-10597391-B2 Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof NR1H4, FXR1, SLC10A1 KAT6A 2864/4885TP53BP1 4448/4885NLRP3 1663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.